DIVIS LABORATORIES LTD
Divi’s Laboratories shares gain another 5% after Q2 results. Here’s why Jefferies raised target price by 23%
Shares of Divi’s Laboratories jumped 5% following a 64% YoY surge in Q2 FY27 net profit to Rs 1,127 crore. Brokerage Jefferies raised its target price by 23% to Rs 12,550, citing robust CDMO business expansion, strong EBITDA margins, and a solid GLP peptide pipeline.
Divi's Labs shares jump 8% to fresh 52-week high after Q2 profit soars 64% YoY. What brokerages say after bumper results?
Divi’s Laboratories shares surged over 8% during Muhurat Trading, hitting a 52-week high after Q2 FY27 net profit jumped 64% to ₹1,127 crore. Revenue grew 35%, while brokerages differed on valuation concerns and future growth prospects.
Stocks in news: M&M, BHEL, Adani Enterprises, Wipro, Tata Steel, Siemens and Divi's Labs
Indian equity markets ended marginally lower on Sunday, breaking a seven-session winning streak. The NSE Nifty 50 decreased by 44 points, closing at 24,986. Several companies, including Adani Enterprises and Tata Steel, announced important corporate developments and new investments. Wipro appointed a new CEO for its Americas unit, while various firms reported their quarterly earnings. Overall, investors remain cautious as they monitor these announcements and future market movements.
Divi's Labs Q2 Results: PAT surges 64% YoY to Rs 1,127 crore; revenue jumps 35%
Divi's Laboratories has achieved a remarkable profit surge of 63.6% year-on-year for the September quarter of FY27, driven by a 35.4% increase in operational revenue, totaling Rs 3,676 crore. The company's total income reached Rs 3,770 crore in Q2FY27, while the first half of the fiscal year saw total earnings hit Rs 6,907 crore.
Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return
In 2026, India's pharmaceutical stocks are making headlines with impressive year-to-date gains. This surge is driven by strong domestic demand alongside enhanced profitability from new product launches. Notable players like Laurus Labs and Gland Pharma have recorded remarkable returns, topping 100%. Amid challenges faced by other sectors, the pharmaceutical field demonstrates resilience. Analysts are optimistic but advise exercising caution regarding potential market volatility and the durability of this sector's performance.
- Go To Page 1
Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%
The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosystem charge. And both the government and the courts have stepped in. At one level, that is not entirely a bad thing. Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. SR+ Reports is a complimentary offering to ETPrime members.
GLP-1 boom in China, India, Brazil could create $22 billion market by 2035, J.P. Morgan says
The China-India-Brazil market for GLP-1 weight-loss drugs could expand to $22 billion by 2035 from $6.6 billion currently, J.P. Morgan estimates. Improving affordability, generic launches and wider access could drive adoption, though penetration remains low, particularly in India, where cost concerns and cultural resistance to injectable treatments remain key barriers.
Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players
India's pharmaceutical companies are expected to have a mixed performance in the upcoming September quarter. Companies like Sun Pharmaceutical Industries and Aurobindo Pharma are likely to report good growth. In contrast, Dr Reddy's Laboratories and Lupin may face challenges due to increased competition and a high base. Pricing pressure and elevated raw material costs are also expected to impact overall performance.
Sunil Singhania-backed Abakkus Flexi Cap Fund increases stake in RIL, HDFC Bank, Groww, and 32 others in September
Sunil Singhania-founded Abakkus Flexi Cap Fund increased holdings in Reliance Industries, HDFC Bank, Groww and 32 other stocks in September. The fund also added Zydus Lifesciences, exited Cyient DLM and trimmed stakes in two stocks.
Jefferies lists 6 factors that will shape CRDMO winners; Divi’s Labs, Sai Life, Laurus, Anthem among stocks to watch
India's CRDMO sector is on the brink of expansion, backed by solid partnerships with major pharmaceutical players and comprehensive capabilities. Jefferies emphasizes the critical role of specialized manufacturing skills and a strong project pipeline for achieving success. With Divi's Laboratories and Sai Life Sciences excelling in these domains, there is potential for notable earnings growth.
When nothing is cheap, winners may come from any corner: 19 stocks with downside to upside potential of -28% to plus 22%
Because each pharma company took a different road, they no longer rise and fall together. Where any one of them stands in 10 years depends on what it chose in the last five or six. So, one name can do wonderfully while the one sitting next to it does very little. Stock Reports Plus, powered by Refinitiv, is a comprehensive report that evaluates five key components of 4,000+ listed stocks – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. The simple average of the above-mentioned five component ratings is normally distributed to reach an average score.
Divi's Labs, TVS Motor could replace Max Healthcare, HDFC Life in NSE's March 2027 index review
Divi's Laboratories and TVS Motor Company have emerged as likely contenders to replace Max Healthcare Institute and HDFC Life in the Nifty index at the March 2027 review. According to Quiddity Leaderboard, this transition may lead to significant inflows estimated at around $824 million. As the review remains in its nascent phase, further alterations to the Nifty 100 rankings are also projected.
F&O Radar: Bull Call Spread strategy for Divi’s Laboratories this week
Divi’s Laboratories remains in a strong uptrend after a multi-year breakout, with supportive momentum and options data pointing to further upside. Analysts see Rs 9,800 as a key hurdle and Rs 10,000 as the next potential level.
MF Tracker: HDFC Pharma & Healthcare Fund tops equity MFs at 25% in 1 year. Should investors chase the rally?
HDFC Pharma and Healthcare Fund recorded an impressive 25% return in the last year, surpassing its category average across various time frames. The robust performance is primarily due to heightened demand for generic drugs and recent FDA approvals. Investors are advised to steer clear of merely chasing past successes and instead focus on a sustainable long-term strategy.
Sunil Singhania-backed Abakkus Flexi Cap Fund increases stake in Dixon Technologies, OFSS, 30 others in August
Sunil Singhania-backed Abakkus Flexi Cap Fund increased its holdings in 32 stocks during August, including Dixon Technologies, OFSS, NTPC, and Tata Steel. The fund also added Groww and Jubilant Pharmova as new entrants, expanding its AUM to Rs 7,394 crore across 46 portfolio stocks.
Only 2 of 23 mutual fund themes gained in August; IPO, defence stay green as auto, railways and tech slide : Report
Only two of 23 mutual fund themes, IPO and defence, gained in August as domestic equities faced broad-based pressure, according to Vallum Capital. Auto, railways and technology were among the biggest laggards, while equity fund inflows fell sharply. Commodities remained the strongest performer on a year-to-date basis despite a monthly decline.
JioBlackRock Mutual Fund files draft document with Sebi for income plus arbitrage omni FoF
JioBlackRock Mutual Fund has filed draft documents with Sebi for an income plus arbitrage omni FoF, which will invest in debt-oriented and arbitrage funds. The open-ended scheme will offer regular and direct plans with growth options, a Rs 500 minimum investment and a benchmark combining debt and arbitrage indices.
Explained: When should mutual fund investors use CAGR, XIRR or IRR to calculate returns?
CAGR, XIRR and IRR are commonly used to measure mutual fund returns, but each serves a different purpose. While CAGR is suited to lumpsum investments, XIRR helps calculate returns from irregular cash flows such as SIPs. IRR can be used to assess returns from investments involving multiple cash flows over time.
Bitcoin holds near $77K despite hawkish Fed, CLARITY Act setback and weak ETF demand. Here is what experts say
Bitcoin held near $77,000 despite a hawkish Federal Reserve, weak crypto ETF flows and a Senate setback for the CLARITY Act. Experts said the cryptocurrency remains in a cautious recovery phase, with support around $76,000-$76,100 and resistance near $76,850-$77,000, while volatile ETF flows signal investor caution.
Capitalmind Flexi Cap Fund adds Divi’s Laboratories, Bajaj Auto and 3 other stocks in August
Capitalmind Flexi Cap Fund made five fresh additions and completely exited five stocks from its portfolio in August, while keeping its exposure unchanged in 27 stocks. The fund had 32 stocks across 17 sectors, with healthcare accounting for the largest allocation. Here’s a look at the stocks added and exited, sector allocation and the fund’s performance since inception.
Sell Divi's Laboratories, target price Rs 4,500: ICICI Securities
ICICI Securities recommends a sell on Divi's Laboratories with a target price of Rs 4,500 despite recent quarterly growth. Management remains optimistic about future revenue growth driven by custom synthesis and new projects. Promoters hold a significant 51.89% stake, with FIIs and DIIs owning substantial shares. The company aims for commercial success in its Kakinada plant.
Divis Labs shares 0.42% as Nifty gains
The stock quoted a 52-week high price of Rs 6448.75 and low of Rs 3350.05.
Share price of Divis Labs falls as Nifty weakens
A total of 2,065 shares changed hands on the counter till 01:08PM (IST).
Divis Labs shares down 1.14% as Nifty gains
The stock quoted a 52-week high price of Rs 5582.85 and low of Rs 3300.0.
Buy Divi's Laboratories, target price Rs 3742: ICICI Direct
Divi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 98115.86 Crore) operating in Pharmaceuticals sector.
Buy Divi's Laboratories, target price Rs 3762: ICICI Direct
Divi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 99034.38 Crore) operating in Pharmaceuticals sector.
Load More
